Dimension Capital Closes $800M Fund III as Science Meets Compute
TL;DR
Dimension Capital, the New York and San Francisco firm founded in late 2022 by Zavain Dar, Adam Goulburn and Nan Li, has closed an $800 million third fund. That is 60% larger than the $500 million Fund II it announced roughly 18 months earlier, and it lifts the firm's total assets under management to approximately $1.65 billion. The raise matters less for its headline number than for what it certifies: the boundary between life sciences investing and frontier software investing has effectively dissolved, and LPs are now willing to fund that convergence at scale in a market where most sub-decade-old managers cannot get a second meeting.
Key Takeaways
A four-year-old firm raised three funds in a market that punishes emerging managers. The prevailing story of 2024-2026 fundraising has been brutal concentration, with LP dollars flowing to a shrinking set of established brands while newer GPs stall out between Fund I and Fund II. Dimension has done the opposite, compounding fund size roughly 60% per vintage on an 18-month cadence. That pace is normally reserved for firms with a decade of distributions behind them.
The step-up is a referendum on a thesis, not on DPI. A firm founded in late 2022 has not returned meaningful capital yet. What it has is a mark-to-market story that is difficult to ignore: Chai Discovery, which Dimension co-led at seed with a $30 million round in 2024, raised $400 million at a $3.8 billion valuation in July 2026. New Limit, backed at Series A in January 2025, completed a Series C at a $3.1 billion valuation. LPs are underwriting velocity of markup, which is a rational but not risk-free basis for a re-up.
The Anthropic position is the most interesting line on the balance sheet. Anthropic acquired Dimension portfolio company Coefficient Bio in spring 2026 in a deal reported at around $400 million, and Dimension took shares in the acquirer. Owning a slice of a frontier lab because your drug discovery company was absorbed into it is the cleanest possible illustration of the firm's thesis, and it also creates an unusual exposure profile for a nominally life-sciences-adjacent fund.
Multistage is a deliberate structural choice, not scope creep. Dimension describes itself as a multistage, research-oriented investor. At $800 million, that structure lets it seed a Chai Discovery at $30 million and then defend ownership through a $400 million round without syndicating away the position. In a category where the winners are compounding valuations at unusual speed, the ability to follow on is arguably worth more than entry price discipline.
Fund Overview
Fund Name: Dimension III
Fund Size: $800 million (Fund II was $500 million; total AUM approximately $1.65 billion)
Stage: Multistage, from seed through growth
Check Size: Not formally disclosed; the firm has co-led seed rounds in the $30 million range and follows on into later rounds
Geography: Primarily US, with offices in New York and San Francisco
Focus: The intersection of science and compute, including AI for biology, drug discovery, materials research, lab automation and adjacent hardware
Key LPs: Not publicly disclosed
Why This Fund Matters
For two decades, life sciences venture and technology venture operated as separate industries with separate LPs, separate diligence norms and separate exit expectations. Biotech investors underwrote clinical risk on ten-year horizons with syndicated tranches tied to milestones. Software investors underwrote distribution risk and expected compounding revenue. The two rarely competed for the same deal.
That separation has collapsed. When a drug discovery company's core asset is a foundation model rather than a molecule, the diligence question changes from "will this pass Phase II" to "does this team have the data, the compute and the model architecture to stay ahead." That is a technology question, and it is one that a generalist frontier-tech investor is often better equipped to answer than a traditional biotech specialist. Dimension was built explicitly for that question, and its three founders come from exactly the right pedigree: Dar and Goulburn were partners at Lux Capital, a firm that has spent fifteen years refusing to respect the biotech-software boundary, and Li came from Obvious Ventures.
The macro backdrop is more favourable than the headline biotech numbers suggest. Traditional therapeutics venture has been in a multi-year drawdown, with IPO windows narrow and crossover investors retrenching. But capital has not left the sector so much as it has migrated to the compute-adjacent end of it. Anthropic buying a drug discovery platform outright is a signal that frontier labs now view biology as an application layer worth owning rather than partnering into. That is a fundamentally different exit map than the biotech industry has operated under, and it favours investors positioned at the seam.
There is a cautionary reading too. The $800 million number is being justified by a portfolio whose value is overwhelmingly unrealised and concentrated in a small number of companies that have repriced very fast in a very hot market. Chai Discovery at $3.8 billion and New Limit at $3.1 billion are extraordinary paper outcomes for positions entered at seed and Series A within the last two years. If AI-for-science valuations compress the way AI application valuations did in prior cycles, Fund II's marks will look materially different, and Fund IV will be a much harder conversation.
The Team
Dimension was founded in late 2022 by three partners. Zavain Dar and Adam Goulburn were both previously partners at Lux Capital, where they invested across the frontier of computational biology, AI and deep tech. Nan Li joined from Obvious Ventures. The firm has consistently presented itself as a three-partner, research-led shop rather than a platform with a large investment bench, and that concentration is part of the pitch: a small partnership with genuine technical depth can move on a seed round in a novel category faster than a committee.
The team's differentiating claim is technical literacy at the model layer combined with genuine biology domain knowledge. In practice that shows up as willingness to co-lead at seed in companies where the product is a foundation model with no revenue and no clinical asset, which is a position most traditional life sciences funds are structurally unable to take and most software funds are unwilling to underwrite.
Early Portfolio
Publicly reported positions across Dimension's funds include Chai Discovery, developing open-source AI foundation models for drug development, which raised $400 million at a $3.8 billion valuation in July 2026 after Dimension co-led its $30 million seed in 2024. New Limit, the longevity and epigenetic reprogramming company co-founded by Coinbase CEO Brian Armstrong, which Dimension backed at Series A in January 2025 and which completed a Series C at a $3.1 billion valuation in July 2026. Coefficient Bio, a drug discovery platform acquired by Anthropic in spring 2026 in a deal reported at roughly $400 million, converting Dimension's position into equity in Anthropic. The firm has also backed inference infrastructure company Modal Labs.
What This Means for Founders
If you are building a company where the defensible asset is a model, a dataset or an automated experimental loop applied to a scientific domain, Dimension is close to a purpose-built buyer. The firm is unusually comfortable with pre-revenue, pre-clinical technical risk and it has demonstrated it will write a meaningful first cheque rather than a token seed. The multistage structure also means a seed relationship is a real option on Series B and C capital, which matters enormously in a category where the good companies raise every nine months at aggressive step-ups.
The corollary is that this is not a fund for incremental science. A three-partner firm deploying $800 million across a multistage portfolio is running a concentrated book and needs each position to be capable of a very large outcome. Founders working on well-understood therapeutic modalities, service-layer tooling for pharma, or anything whose ceiling is a $200 million trade sale will find the conversation short. Come with a claim about why your approach compounds, and be ready to defend it at the architecture level rather than the narrative level.
Fund Momentum Take
This is one of the more impressive emerging-manager fundraising performances of the cycle, and it deserves to be read as such. Going from zero to $1.65 billion in AUM in under four years, in a fundraising environment that has been openly hostile to anyone without a decade of DPI, means Dimension's LPs are not merely tolerating the thesis, they are actively competing to increase allocation. The 60% step-up on an 18-month cadence is the tell.
Our reservation is the one that always attaches to velocity: the evidence base is marks, not distributions. Chai Discovery and New Limit are genuinely exceptional outcomes on paper, but a firm founded in late 2022 has had no opportunity to demonstrate that it can convert paper into cash in a market that is not cooperating. The Anthropic equity received via the Coefficient Bio acquisition is real value, but it is also illiquid and correlated with exactly the same AI sentiment that is driving the rest of the book. A three-partner team deploying $800 million multistage will also feel real strain on the reserve management side; deciding which of twenty positions deserves defence at a 5x markup is a materially harder job than picking seeds.
Our bet is that the thesis is right and the timing is early enough to matter. The convergence of AI and the physical sciences is not a cycle artefact, and the firms that built dedicated infrastructure for it in 2022 and 2023 will have a durable sourcing advantage over the generalists arriving now. We would watch two things: whether Dimension expands the partnership to support the larger fund, and whether the first realisations arrive in the next 24 months at anything close to the carrying marks. If both go well, Fund IV is a $1.5 billion conversation.
Frequently Asked Questions
How large is Dimension Capital's third fund?
Dimension III closed at $800 million, roughly 60% larger than the firm's $500 million second fund announced about 18 months earlier. Total assets under management are approximately $1.65 billion.
Who runs Dimension Capital?
The firm was founded in late 2022 by Zavain Dar and Adam Goulburn, both previously partners at Lux Capital, and Nan Li, previously of Obvious Ventures.
What does Dimension invest in?
Dimension describes itself as a multistage, research-oriented investor at the intersection of science and compute. In practice that means AI applied to biology, drug discovery, materials research, lab automation and related hardware and infrastructure.
Why does Dimension hold equity in Anthropic?
Anthropic acquired Dimension portfolio company Coefficient Bio, a drug discovery platform, in spring 2026 in a deal reported at approximately $400 million. Dimension received shares in Anthropic as part of that transaction.
What are Dimension's most notable portfolio companies?
Publicly reported positions include Chai Discovery, which raised $400 million at a $3.8 billion valuation in July 2026, longevity company New Limit, which reached a $3.1 billion valuation, inference company Modal Labs, and the now-acquired Coefficient Bio.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.